
MGTX Stock Forecast & Price Target
MGTX Analyst Ratings
Bulls say
MeiraGTx Holdings PLC is poised for a positive trajectory with an extended financial runway projected through 2027, following the anticipated closing of the Hologen deal. The company's focus on providing one-time functional cures in ophthalmology has shown promising outcomes, as evidenced by the improvement in binocular visual acuity across all patients in recent trials and significant benefits in patient-reported outcomes. Furthermore, the planned Biologics License Application (BLA) filing in 2026, combined with the promising Phase II trial results and RMAT designation, underscores the potential for significant advancements in gene therapy for various disorders.
Bears say
The fundamental reasons for the negative outlook on MeiraGTx Holdings PLC's stock can be attributed to significant uncertainties surrounding regulatory approvals for its gene therapy products, which could lead to downward revisions in risk-adjusted projections and financial estimates. Additionally, the company's recent net loss of $148 million, equating to an earnings per share (EPS) of ($2.12), exceeded earlier estimates, indicating financial strain. Finally, the potential for manufacturing challenges and a pricing structure that may not align with established norms in the therapeutic market further compounds the risks associated with the company's current and future financial performance.
This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.
MGTX Analyst Forecast & Price Prediction
Start investing in MGTX
Order type
Buy in
Order amount
Est. shares
0 shares